Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

Press/Media

Period	16 Feb 2023

Media coverage

Title	Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
Media name/outlet	Indian Pharma Industry : Policies
Country/Territory	India
Date	16/02/23
URL	ct.moreover.com/?a=50026726508&p=1gw&v=1&x=V4zfien_fc8AGWra5Ez5xg
Persons	Mauricio Burotto